Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) saw a downside of -6.41% on Friday at $20.57 after subtracting -$1.41. The 5-day average trading volume is 901,317 shares of the company’s common stock. It has gained $24.25 in the past week and touched a new high 1 time within the past 5 days. An average of 775,479 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 964,656.
ORMP’s 1-month performance is 11.69% or $0.17 on its low of $17.79 reached on 09/02/21. The company’s shares have touched a 52-week low of $2.40 and high of $24.25, with the stock’s rally to the 52-week high happening on 09/27/21. YTD, ORMP has achieved 418.40% or $16.12 and has reached a new high 29 times. However, the current price is down -15.17%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Sep 16, 15 days have gone by since the last insider trading activity for Oramed Pharmaceuticals Inc. (ORMP). RAKIN KEVIN (Director) most recently sold 21,100 shares at $20.99 per share on Sep 16. This transaction cost the insider $442,830. President and CEO, KIDRON NADAV, sold 220,000 shares at a price of $20.11 on Aug 09.
Oramed Pharmaceuticals Inc. (ORMP) has a trailing price-to-earnings (P/E) ratio of 33.74 for the broader industry and 32.31 for the sector, meaning that investors are optimistic about the stock’s future prospects. ORMP stock has a beta of 1.92. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 257.33 while the price-to-book (PB) in the most recent quarter is 9.64.
Oramed Pharmaceuticals Inc.’s quick ratio for the period ended May 30 was 12.60, with the current ratio over the same period at 12.60 meaning that ORMP stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending May 30 was 0.00, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is -433.58%. The firm’s gross profit as reported stood at $2.71 million against revenue of $2.71 million.
The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. Oramed Pharmaceuticals Inc.’s return on assets over the past 12 months stands at -32.30%. Return on investment over the past year is -35.70%, while its return on equity (ROE) trailing 12 months is -41.20%. In comparison, the average ROE for the broader industry over the past year is -36.91.
For the quarterly period ending May 30 this year, Oramed Pharmaceuticals Inc.’s cash and short-term investments amounted to $12.23 million against total debt of $0.56 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected ORMP to announce -$0.2 per share in earnings in its latest quarter, but it posted -$0.17, representing a 15.00% surprise. EBITDA for the quarter stood at more than -$6.09 million. ORMP stock balance sheet for the quarter ending May 30 shows that total liabilities totaled 11.3 million, with total debt at $0.56 million. Shareholders hold equity totaling $32.51 million
Let’s look briefly at Oramed Pharmaceuticals Inc. (ORMP) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 30 September was 46.31% to suggest the stock is trending Neutral, with historical volatility in this time period at 77.87%.
The stock’s 5-day moving average is $22.23, reflecting a -10.27% or -$2.33 change from its current price. ORMP is currently trading +10.35% above its 20-day SMA, +83.42% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +55.90% and +383.61% respectively.
Stochastic %K and %D was 53.14% and 65.69% and the average true range (ATR) pointed at 1.67. The RSI (14) points at 51.24%, while the 14-day stochastic is at 32.23% with the period’s ATR at 1.65. The stock’s 9-day MACD Oscillator is pointing at -0.15 and 0.53 on the 14-day charts.
In the most recent analyst report for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), Canaccord Genuity launched coverage with a Buy rating. Analysts offering their rating for ORMP stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ORMP as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is ORMP’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $25.00 and a high of $30.00, with their median price target at $27.50. Looking at these predictions, the average price target given by analysts is for Oramed Pharmaceuticals Inc. (ORMP) stock is $27.50.